Differences in frailty in older men and women
Authors: Emily H Gordon and Ruth E Hubbard
Published online: 27 January 2020
Compared with age-matched men, women tend to have poorer health status but longer life expectancy
Summary
- Frailty describes an individual's vulnerability to adverse health outcomes and is a useful construct that assists health professionals to understand the heterogeneity of the ageing population.
- While the pathophysiological pathways that lead to frailty are not well defined, an individual's sex appears to be a key factor influencing the ageing trajectory.
- Compared with age‐matched men, women tend to have poorer health status (ie, they are more frail) but longer life expectancy (ie, they are more resilient). It seems likely that a combination of biological, behavioural and social factors underpin this male–female health–survival paradox.
- Randomised controlled trial data for frailty interventions in older adults are emerging, with multicomponent programs incorporating exercise and nutrition‐based strategies showing promise. Pharmaceutical and other innovative therapeutic strategies for frailty are highly anticipated.
- Sex differences in the effectiveness of frailty interventions have not been addressed in the research literature to date. In the future, successful interventions may target many (if not all) biopsychosocial domains, with careful consideration of issues relevant to each sex.
In simple terms, ageing is an accumulation of cellular damage over time. Yet there is significant heterogeneity in the older population in terms of health status and care needs; some individuals remain functionally independent into their tenth decade whereas others have complex comorbidities and psychosocial problems from middle age. This variability suggests that ageing is not a fixed process and has stimulated research exploring the lifestyle and behavioural factors that promote healthy ageing and the pathophysiological processes that may lead to frailty. It is increasingly recognised in this research that the ageing trajectory is influenced by an individual's sex.
Here, we introduce the frailty construct before reviewing differences in the frailty of men and women. We also summarise the evidence for frailty interventions in older adults and consider whether, in the future, clinicians may be recommending sex‐specific management strategies. For this review, we searched PubMed and other databases for peer‐reviewed articles using various search terms, including “frailty”, “sex differences” and “intervention”.
Frailty
Frailty has been defined as a state of increased vulnerability that is associated with adverse health outcomes.1 It has been estimated that just over 10% of community dwelling adults aged 65 years and over are frail.2 A frail older person takes longer to recover after any sort of insult (such as infection, infarction or adverse drug reactions) and during the period of recovery is more vulnerable to further stressors. Increasing frailty is associated with syndromic disease presentations; falls, delirium, functional decline and new urinary incontinence may reflect acute illness in a frail older person and should never be dismissed as “normal for age”.1
The prevalence of frailty increases with age, and chronic inflammation has been proposed as the key pathogenic factor in both ageing3 and frailty.4 However, since the exact aetiology of frailty is yet to be established, many different models have been developed to describe the clinical entity of frailty. Some measures define frailty as a phenotype, a set of symptoms and signs that occur together. The most widely used phenotypic model was defined by Fried and colleagues5 as the presence of three or more of the following: weight loss, weakness, slowness, fatigue and low physical activity. Individuals with one or two of these criteria were defined as “pre‐frail”. In their landmark study, falls, worsening disability, hospitalisations and death were more common in pre‐frail and frail individuals.5
The cumulative deficit model, represented by the Frailty Index (FI), is another commonly used method to quantify frailty. The underlying principle is that the more problems an individual acquires, the more likely they are to be frail.6 Here, an index is derived from a list of variables (deficits) which should encompass functional, cognitive, physiological and psychosocial domains.7 Signs, symptoms, disabilities and diseases may be included as deficits if they fulfil certain criteria: accumulation with age; association with adverse outcome; and absence of early saturation (eg, presbyopia is fairly ubiquitous after age 55 years so would not be included as a deficit).7 As long as these criteria are met and more than 30 deficits are included, an FI can be derived from datasets comprising different numbers and types of deficits (eg, someone with ten deficits from a total of 40 has an FI of 0.25; someone with 21 deficits from a total of 70 has an FI of 0.30). The FI is a continuous variable, which not only provides information about frailty severity but also enables quantification of the health status of individuals identified as non‐frail by the phenotypic model. Studies have found that the FI predicts adverse outcomes, including institutionalisation and mortality, in a dose‐dependent manner.6,8 Interestingly, it is the number of deficits, rather than the nature of the deficits, that influences the relationship between FI and adverse outcomes.6 The predictive validity of the FI has been confirmed by multiple studies using cohorts from different cultural backgrounds.
Other frailty assessment tools are generally derived from these two key conceptual models, but there is no current consensus as to a standardised tool for frailty measurement. In a 2011 review, 20 frailty instruments were identified;9 4 years later, 29 instruments were described;10 and by 2018, 89 different measures were being utilised in the acute care setting alone.11 Different tools yield different estimates of frailty prevalence and vary in their content validity, predictive validity and feasibility.9,10 While there is some overlap in identification of frailty, it is likely that these models (and their associated assessment tools) capture slightly different groups.
Interest in frailty has spread beyond geriatric medicine to other medical, surgical and critical care specialties in recent years. With improvements in the medical management of acute and chronic diseases, more adults are living to an advanced age and, as a result, subspecialty areas, such as oncology and cardiothoracic surgery, are seeking to validate frailty as a prognostic tool to guide their management.12 In Australian acute medical units, the prevalence of frailty has been estimated to be between 50% and 88% (depending upon the frailty measure used).13,14 Frail inpatients face many adverse outcomes, including falls, pressure injuries, delirium, prolonged hospitalisation, discharge to a nursing home, and death in hospital.15
Sex differences in frailty
In community dwelling populations aged over 65 years, women are more likely to be frail and to have a greater burden of frailty than men of the same age.2,16 Yet women appear to be more resilient — at any given age or level of frailty, their mortality rates are lower.16
This sex–frailty paradox is another conceptualisation of the male–female health–survival paradox, which has long been reported in the literature. The female survival advantage has been documented by European historical records dating back to the 18th century,17 and in Australia, the life expectancy of females continues to be about 4 years longer than that of males.18 Yet throughout their lives, women are burdened by chronic disease and disability to a greater extent than men and, unsurprisingly, women have poorer self‐rated health.19
Several biological, behavioural and social explanations for sex differences in morbidity and mortality have been proposed and tested by researchers. More recently, attention has turned to sex differences in frailty (Box 1). It seems likely that the pathophysiology of the sex–frailty paradox comprises many, if not all, of these factors. In terms of biopsychosocial pathways to frailty, much more needs to be done to better understand why and how men and women age in different ways.
Frailty interventions
Over the past 20 years, research efforts have focused on refining frailty measurement and establishing its prognostic implications. While it is important to be able to describe the heterogeneity of an ageing population and to define risks of adverse outcomes, it is equally important to develop and test therapeutic strategies for frailty. Given its negative consequences, it is tempting to view frailty from a nihilistic standpoint. However, improvements in health can occur in individuals of any age, with varying degrees of frailty.35
While there are many intervention studies of frail older adults, there are few studies specifically addressing the treatment of frailty. Two recent reviews have sought to clarify the effectiveness of frailty interventions in adults aged 65 years and over.36,37 A 2018 systematic review included 21 randomised controlled trials published between 2002 and 2016,36 and a 2017 scoping review included 12 randomised controlled trials and two cohort studies published during the same period.37 Most of the evidence in the included studies was graded as low quality, meta‐analysis could not be undertaken, and only four studies were common to both reviews. It was challenging for the authors of these reviews to synthesise the results for many reasons, but a key issue was heterogeneity of the frailty measurement. The impact of the intervention was also measured in various ways, including change in the prevalence of frailty and pre‐frailty, and change in the prevalence of frailty components. Surrogate measures for frailty (such as physical performance scores, functional status, muscle mass and power) were frequently used. These methodological challenges highlight that this field of enquiry is still in its infancy.
Nevertheless, based upon the current available evidence, there are interventions that may have the potential to reduce the prevalence of frailty (or its components) or to prevent the progression of frailty in older adults (Box 2). At present, exercise and nutrition‐based interventions have the highest level of evidence.36
Many of these interventions target phenotypic features of frailty, including weakness, slowness and wasting. Yet frailty is more than just physical signs and symptoms. Cognitive training strategies and comprehensive geriatric assessment with interdisciplinary interventions address important non‐physical health domains. More recently, researchers have reported benefits from multifactorial interventions incorporating exercise, a nutritional intervention, and cognitive training with social support40 or medication review.41
Criticisms of the available frailty interventions include imperfect treatment compliance, variable durability of effects post‐intervention and cost‐effectiveness. While provisional results regarding these issues are reassuring,36,41,42 further investigation is justified considering the complexity of the interventions and the vast number of potential recipients. It is also important to note that very few studies have examined interventions to prevent the development of frailty in non‐frail older adults. Further, the evidence‐base for interventions to prevent or reduce frailty in institutionalised or hospitalised older adults is limited. Therefore, the available evidence primarily informs management of frail (and pre‐frail) community dwelling adults.
While frailty is not synonymous with chronic disease, the number and severity of comorbidities increase the probability of being frail.43 Bidirectional relationships have been postulated between frailty and several chronic diseases. In some cases, this may be due to shared pathophysiology (eg, cardiovascular and cerebrovascular disease),44 and in other cases, frailty may be linked with chronic disease via functional impairment (eg, osteoporosis with fracture). Consequently, chronic diseases are likely to be important therapeutic targets for frailty.45 However, to our knowledge, frailty is yet to be included as an outcome measure in chronic disease intervention trials and, as a result, the impact of disease management on the incidence and prevalence of frailty may only be inferred.
Smoking, excessive alcohol intake and abdominal obesity have all been strongly linked with frailty in older adults23,46,47 and are key risk factors for the development of many chronic diseases. Again, in theory, management of these variables would reduce the incidence and prevalence of frailty in old age through primary prevention of chronic disease as well through reduced exposure to inflammatory stimuli.
More recently, increasing knowledge of frailty pathophysiology has prompted a search for effective pharmaceutical interventions. Androgen deficiency has been implicated in the development of frailty, particularly sarcopenia, in both sexes. However, the evidence for the therapeutic benefit of hormone replacement is limited. For example, testosterone replacement in pre‐frail and frail men has not led to improvements in physical function,48 and while the combination of dehydroepiandrosterone and exercise improved physical performance in a small study of pre‐frail and frail women,49 a subsequent systematic review did not confirm these results.50 Concerns about the adverse event profile of androgen replacement therapy in older men and women may impact future advances in this area of research.29 Early studies of selective androgen receptor modulators look promising, but larger trials of longer duration are still required.29
If chronic inflammation is a key pathogenic factor in frailty, it is reasonable to hypothesise that anti‐inflammatory agents would be effective in preventing or reducing frailty. While randomised controlled trials in human participants have not been conducted, observational studies suggest that anti‐inflammatory agents may not reduce the risk of frailty. For example, in the Women's Health Initiative Observational Study, current statin use had no effect on incident frailty over 3 years.51 However, a recent intervention trial in ageing mice demonstrated that long term treatment with an angiotensin‐converting enzyme inhibitor reduced pro‐inflammatory cytokine levels and attenuated the progression of frailty.52 While this preclinical evidence seems promising, caution is advised in assuming that inflammation causes frailty.53 An alternative view is that inflammatory markers become elevated in response to chronic stimuli or are an epiphenomenon unrelated to the core pathophysiology.53 In these scenarios, anti‐inflammatory agents would be, at the very least, ineffective or, at the very worst, harmful.
Fortunately, frailty researchers continue to pursue innovative therapeutic options. For example, a phase 2 randomised double‐blind controlled trial of allogeneic mesenchymal stem cell transplantation in older frail adults recently demonstrated a reassuring safety profile, as well as some promising results with respect to physical performance and function.54 Even so, at the present time, non‐pharmacological interventions, particularly exercise and nutrition programs (or combinations of such), are the recommended treatment for frailty in community dwelling older adults.36
The sex–frailty paradox and frailty interventions
Sex differences in the effectiveness of interventions have not been specifically addressed by the research literature to date. Exercise programs appear to be effective in both sexes.36 However, sarcopenia, low physical activity and functional impairment are more prevalent in older women than men,29 and it is possible that women may benefit from a different type or intensity of exercise intervention than men. With respect to nutrition, men may benefit from interventions to a greater extent than women. Several studies have indicated that men tend to have a poorer understanding of nutrition and make unhealthy dietary decisions.55 A recent study recruited 4421 participants with, or at high risk of, knee osteoarthritis,56 and explored the components of their diet at baseline. Over an 8‐year follow‐up period, men who consumed a diet with high inflammatory potential had up to four times the risk of developing frailty than men who did not; however, diet had no effect on incident frailty for women. It has also been noted that nutrition intervention studies with male and female participants were more likely to be positive than studies with mostly (or only) female participants.36 Overall, it is possible that nutritional support is more beneficial in the prevention and treatment of frailty in men than in women.
Sex differences in frailty highlight that older men and women may respond to interventions in different ways and may benefit from more sex‐specific strategies. The sex–frailty paradox adds yet another dimension by highlighting that the link between frailty and mortality is not fixed; even though men are less frail than women, we must not forget that they are more likely to die. Thus, while it is important for health care professionals to ask how we can prevent and treat frailty in ageing men and women, it may also be useful to consider how can we prevent and treat frailty, particularly in ageing women. And how do we prevent death, particularly in ageing men?
Like frailty, we can conceptualise the sex–frailty paradox to be an accumulation of deficits across multiple systems: biological, behavioural and social. Successful interventions, therefore, are likely to target many (if not all) domains with careful consideration of issues relevant to each sex (as outlined in Box 1). In Box 3 we propose sex‐specific strategies for prevention and treatment of frailty.
Conclusion
Caring for frail older adults is a core remit of our health care system. A better understanding of frailty should improve our care of the ageing population through earlier identification of at‐risk patients, development of intervention strategies, and more effective use of health care resources. To provide optimal, patient‐centred care, sex differences should inform our practice. While the evidence base for sex‐specific frailty interventions is lacking at present, the knowledge gleaned and hypotheses generated from observational data should inspire programs of research, instigate public health initiatives, and prompt reflection by health professionals.
Box 1 – Biological, behavioural and social hypotheses regarding sex differences in mortality, morbidity and frailty
|
Category |
Comments |
||||||||||||||
|
|
|||||||||||||||
|
Biological |
Genetic |
|
|||||||||||||
|
|
Hormonal |
||||||||||||||
|
|
Immunological |
|
|||||||||||||
|
|
Reproduction |
|
|||||||||||||
|
|
Chronic disease |
|
|||||||||||||
|
|
Disability |
||||||||||||||
|
|
Physiological reserve |
|
|||||||||||||
|
Behavioural |
Risk‐related activities |
|
|||||||||||||
|
|
Illness perception |
|
|||||||||||||
|
|
Health reporting behaviour |
|
|||||||||||||
|
|
Health care use |
||||||||||||||
|
Social |
Gender roles |
|
|||||||||||||
|
|
Social assets and deficits |
|
|||||||||||||
|
|
|||||||||||||||
|
|
|||||||||||||||
Box 2 – Summary of evidence for frailty interventions36,37
|
Intervention |
Impact on frailty |
Comments |
|||||||||||||
|
|
|||||||||||||||
|
Exercise
|
Exercise is generally considered to be an effective intervention for frailty.
|
The most effective program (ie, type of training, intensity or duration) has not been established although training in groups appears to be more effective than home‐based programs. |
|||||||||||||
|
Nutrition
|
Nutritional supplementation is generally considered to be an effective intervention for frailty.
|
The most effective nutritional program (ie, type of supplement or duration) has not been established. |
|||||||||||||
|
Multicomponent interventions
|
Multicomponent interventions, comprising exercise and nutrition programs (± cognitive training), are generally considered to be effective interventions for frailty.
|
Components appeared to have additive effects. That is, the benefit of a multicomponent intervention was not solely attributed to the exercise program. |
|||||||||||||
|
Cognitive training
|
The evidence for cognitive training alone as an intervention for frailty is limited.
|
Only one study has been reported to examine the effects of cognitive training alone on frailty.38 |
|||||||||||||
|
Comprehensive Geriatric Assessment (CGA)
|
The evidence for CGA as an intervention for frailty is mixed.
|
The CGA intervention did not impact frailty in all studies. The effectiveness of this intervention appeared to differ depending upon the setting, the target population, the assessment process and the delivery of interdisciplinary interventions. Even so, CGA is of proven benefit for older people in hospital, increasing the likelihood that they will be alive and in their own homes at follow‐up.39 |
|||||||||||||
|
Education sessions and home visits
|
The evidence for education sessions and home visits as interventions for frailty is mixed.
|
The provision of an alert button was the only home visit intervention found to impact frailty. |
|||||||||||||
|
|
|||||||||||||||
|
|
|||||||||||||||
Box 3 – Potential sex‐specific targets for the prevention and treatment of frailty
- Education and support for boys and men regarding appropriate illness and help‐seeking behaviour
- Education and support for boys and men regarding risk‐related behaviour, including smoking, excessive alcohol intake and illicit drug use
- Primary prevention of vascular disease in middle‐aged men through smoking cessation, weight management, physical activity, screening for metabolic disease and pharmaceutical interventions (when appropriate)
- Aggressive management and secondary prevention of vascular disease in middle‐aged and older men
- Nutritional education and support
- Management of sensory impairments, particularly hearing impairment
- Promotion of health care utilisation for preventive and early interventions in middle‐aged and older men
- Promotion and facilitation of social and practical support networks for middle‐aged and older men, particularly those recently widowed or single
Competing interests
No relevant disclosures.
References
- Clegg A, Young J, Iliffe S, Olde Rikkert M, Rockwood K. Frailty in elderly people. Lancet 2013; 381: 752–762.
- Collard R, Boter H, Schoevers R. Prevalence of frailty in community‐dwelling older persons: a systematic review. J Am Geriatr Soc 2012; 60: 1487–1492.
- Franceschi C, Capri M, Monti D, et al. Inflammaging and anti‐inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev 2007; 128: 92–105.
- Fulop T, Larbi A, Witkowski J, et al. Aging, frailty and age‐related diseases. Biogerontology 2010; 11: 547–563.
- Fried L, Tangen C, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56A: M146–M56.
- Mitnitski A, Mogilner A, Rockwood K. Accumulation of deficits as a proxy measure of aging. Sci World J 2001; 1: 323–336.
- Searle S, Mitnitski A, Gahbauer E, Gill T, Rockwood K. A standard procedure for creating a frailty index. BMC Geriatr 2008; 8: 24.
- Rockwood K, Mitnitski A, Song X, et al. Long‐term risks of death and institutionalization of elderly people in relation to deficit accumulation at age 70. J Am Geriatr Soc 2006; 54: 975–979.
- de Vries N, Staal J, van Ravensberg C, et al. Outcome instruments to measure frailty: a systematic review. Ageing Res Rev 2011; 10: 104–114.
- Dent E, Kowal P, Hoogendijk E. Frailty measurement in research and clinical practice: a review. Eur J Intern Med 2016; 31: 3–10.
- Theou O, Squires E, Mallery K, et al. What do we know about frailty in the acute care setting? A scoping review. BMC Geriatr 2018; 18: 139.
- Farcet A, deDecker L, Pauly V, et al. Frailty markers and treatment decisions in patients seen in oncogeriatric clinics: results from the ASRO pilot study. PLoS One 2016; 11: e0149732.
- Hilmer S, Perera V, Mitchell S, et al. The assessment of frailty in older people in acute care. Australas J Ageing 2009; 28: 182–188.
- Rose M, Pan H, Levinson M, Staples M. Can frailty predict complicated care needs and length of stay? Intern Med J 2014; 44: 800–805.
- Hubbard R, Peel N, Samanta M, et al. Frailty status at admission to hospital predicts multiple adverse outcomes. Age Ageing 2017; 46: 801–806.
- Gordon E, Peel N, Samanta M, et al. Sex differences in frailty: a systematic review and meta‐analysis. Exp Gerontol 2017; 89: 30–40.
- Thorslund M, Wastesson J, Agahi N, et al. The rise and fall of women's advantage: a comparison of national trends in life expectancy at age 65 years. Eur J Ageing 2013; 10: 271–277.
- Australian Institute of Health and Welfare. Deaths in Australia (Cat. No. PHE 229). Canberra: AIHW, 2018. https://www.aihw.gov.au/reports/life-expectancy-death/deaths-in-australia/contents/summary (viewed Nov 2019).
- Oksuzyan A, Juel K, Vaupel J, Christensen K. Men: good health and high mortality. Sex differences in health and aging. Aging Clin Exp Res 2008; 20: 91–102.
- Eskes T, Haanen C. Why do women live longer than men? Eur J Obstet Gynecol Reprod Biol 2007; 133: 126–133.
- Gubbels Bupp M. Sex, the aging immune system, and chronic disease. Cell Immunol 2015; 294: 102–110.
- Gale C, Baylis D, Cooper C, Sayer A. Inflammatory markers and incident frailty in men and women: the English Longitudinal Study of Ageing. Age 2013; 35: 2493–2501.
- Hubbard R, Lang I, Llewellyn D, Rockwood K. Frailty, body mass index, and abdominal obesity in older people. J Gerontol A Biol Sci Med Sci 2010; 65A: 377–381.
- Mahendru M, Morris E. Cardiovascular disease in menopause: does the obstetric history have any bearing? Menopause Int 2013; 19: 115–120.
- Crimmins E, Kim J, Sole‐Auro A. Gender differences in health: results from SHARE, ELSA and HRS. Eur J Public Health 2010; 21: 81–91.
- Whitson H, Landerman L, Newman A, et al. Chronic medical conditions and the sex‐based disparity in disability: the Cardiovascular Health Study. J Gerontol A Biol Sci Med Sci 2010; 65A: 1325–1331.
- Ford A, Hankey G, Yeap B, et al. Hearing loss and the risk of dementia in later life. Maturitas 2018; 112: 1–11.
- Hardy S, Allore H, Guo Z, Gill T. Explaining the effect of gender on functional transitions in older persons. Gerontology 2008; 54: 79–86.
- Anderson L, Liu H, Garcia J. Sex differences in muscle wasting. In: Mauvais‐Jarvis F, editor. Sex and gender factors affecting metabolic homeostasis, diabetes and obesity. Springer, 2017.
- Gordon E, Hubbard R. Physiological basis for sex differences in frailty. Curr Opin Physiol 2018; 5: 10–15.
- Verbrugge L. Gender and health: an update on hypotheses and evidence. J Health Soc Behav 1985; 26: 156–182.
- Hibberd J, Pope C. Another look at sex differences in the use of medical care: Illness orientation and the types of morbidities for which services are used. Women Health 1986; 11: 21–36.
- Andrew M, Keefe J. Social vulnerability from a social ecology perspective: a cohort study of older adults from the National Population Health Survey of Canada. BMC Geriatrics 2014; 14: 90.
- Shor E, Roelfs D, Curreli M, et al. Widowhood and mortality: a meta‐analysis and meta‐regression. Demography 2012; 49: 575–606.
- Mitnitski A, Song X, Rockwood K. Improvement and decline in health status from late middle age: modeling age‐related changes in deficit accumulation. Exp Gerontol 2007; 42: 1109–1115.
- Apóstolo J, Cooke R, Bobrowicz‐Campos E, et al. Effectiveness of interventions to prevent pre‐frailty and frailty progression in older adults: a systematic review. JBI Database System Rev Implement Rep 2018; 16: 140–232.
- Puts M, Toubasi S, Andrew M, et al. Interventions to prevent or reduce the level of frailty in community‐dwelling older adults: a scoping review of the literature and international policies. Age Ageing 2017; 46: 383–392.
- Ng TP, Feng L, Nyunt MS, et al. Nutritional, physical, cognitive, and combination interventions and frailty reversal among older adults: a randomized controlled trial. Am J Med 2015; 128: 1225–1236.
- Ellis G, Gardner M, Tsiachristas A, et al. Comprehensive geriatric assessment for older adults admitted to hospital. Cochrane Database Syst Rev 2017; (9): CD006211.
- Luger E, Dorner T, Haider S, et al. Effects of a home‐based and volunteer‐administered physical training, nutritional, and social support program on malnutrition and frailty in older persons: a randomized controlled trial. J Am Med Dir Assoc 2016; 17: 671.e9–.e16.
- Romera‐Liebana L, Orfila F, Segura J, et al. Effects of a primary care‐based multifactorial intervention on physical and cognitive function in frail, elderly individuals: a randomized controlled trial. J Gerontol A Biol Sci Med Sci 2018; 73: 1668–1674.
- Cameron I, Fairhall N, Langron C, et al. A multifactorial interdisciplinary intervention reduces frailty in older people: randomized trial. BMC Med 2013; 11: 65.
- Theou O, Rockwood M, Mitnitski A, Rockwood K. Disability and co‐morbidity in relation to frailty: how much do they overlap? Arch Gerontol Geriatr 2012; 55: e1–e8.
- Fougere B, Boulanger E, Nourhashemi F, et al. Chronic inflammation: accelerator of biological aging. J Gerontol A Biol Sci Med Sci 2017; 72: 1218–1225.
- Jeffrey C, Shum D, Hubbard R. Emerging drug therapies for frailty. Maturitas 2013; 74: 21–25.
- Hubbard R, Searle S, Mitnitski A, Rockwood K. Effect of smoking on the accumulation of deficits, frailty and survival in older adults: a secondary analysis from the Canadian study of health and aging. J Nutr Health Aging 2009; 13: 468–472.
- Shah M, Paulson D, Nguyen V. Alcohol use and frailty risk among older adults over 12 years: the Health and Retirement Study. Clin Gerontol 2018; 41: 315–325.
- Kenny A, Kleppinger A, Annis K, et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty. J Am Geriatr Soc 2010; 58: 1134–1143.
- Kenny A, Boxer R, Kleppinger A, et al. Dehydroepiandrosterone combined with exercise improves muscle strength and physical function in frail older women. J Am Geriatr Soc 2010; 58: 1707–1714.
- Baker W, Karan S, Kenny A. Effect of dehydroepiandrosterone on muscle strength and physical function in older adults: a systematic review. J Am Geriatr Soc 2011; 59: 997–1002.
- LaCroix A, Gray S, Aragaki A, et al. Statin use and incident frailty in women aged 65 years or older: prospective findings from the Women's Health Initiative Observational Study. J Gerontol A Biol Sci Med Sci 2008; 63A: 369–375.
- Keller K, Kane A, Heinza‐Milne S, et al. Chronic treatment with the ACE inhibitor enalapril attenuates the development of frailty and differentially modifies pro‐ and anti‐inflammatory cytokines in aging male and female C57BL/6 mice. J Gerontol A Biol Sci Med Sci 2018; 1–9.
- Hubbard R, Woodhouse K. Frailty, inflammation and the elderly. Biogerontology 2010; 11: 635–641.
- Tompkins B, DiFede D, Khan A, et al. Allogeneic mesenchymal stem cells ameliorate aging frailty: a phase II randomized, double‐blind, placebo‐controlled clinical trial. J Gerontol A Biol Sci Med Sci 2018; 72: 1513–1521.
- Baker A, Wardle J. Sex differences in fruit and vegetable intake in older adults. Appetite 2003; 40: 269–275.
- Shivappa N, Stubbs B, Hebert J, et al. The relationship between the dietary inflammatory index and incident frailty: a longitudinal cohort study. J Am Med Dir Assoc 2017; 19: 77–82.
Linked content
-
MJA Podcast: Dr Emily Gordon
Provenance: Commissioned; externally peer reviewed.
Multimorbidity Clusters Among People Aged 65 Years and Over in Australia: A Nationwide Cross-Sectional Data Linkage Study
Weisi Chen, Christine Y. Lu, Sarah N. Hilmer, Alice A. Gibson, Edwin C. K. Tan
Predictors of Ambulance Transport to Hospital for Older People Living in Tasmanian Aged Care Facilities: A Retrospective Cohort Study
Sharon Andrews, Pieter F. Fouche, Belinda Flanagan, Michael McDermott, Melanie Greenwood
Deprescribing in Older People: A Clinical Practice Guideline Summary
Stephen Tucker, John D. G. Watson, Donna Wellins, Tim Whitmore, Christopher Etherton-Beer, Amy T. Page
Emergency Department Presentations and Hospitalisations for Elder Abuse in People Accessing Aged Care Services in Australia: A Retrospective Cross-Sectional Study
Stephanie L. Harrison, Sahar Barmomanesh, Bryan Morden, Maria C. Inacio, Gillian E. Caughey, on behalf of the ROSA Consumer and Community Advisory Committee
A future for the hospital‐in‐the‐home (HITH) deteriorating patient: shifting the paradigm
Davide R Tomassoni, Iftah Amith
Healthy ageing
Michael Skilton, Alison Williams, Wendy Morgan